Category: Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends

Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends

  1. Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends  CNBC
  2. Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen  Nasdaq
  3. J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market  Endpoints News
  4. Full coverage

from Business – Google News https://www.cnbc.com/2017/09/11/johnson-johnson-unit-terminates-hepatitis-c-development-program.html

Advertisements